bullish

Innovent Biologics Inc

Innovent Biologics (1801 HK) - Have the Genes to Become a Big Pharma

This article mainly analyzed Innovent in terms of its current listed products (Sintilimab, Bevacizumab, Adalimumab and Rituximab), its pipeline, competitive landscape, and also include some concerns.

Equity Bottom-Up
307 Views, 18 Feb 2021 09:54
SUMMARY(Sign Up to Access)
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
  • Unlimited Research Summaries
  • Personalised Alerts
  • Custom Watchlists
  • Company Data & News
  • Events & Webinars
or
Trusted by:
Bloomberg
Societe Generale
SGX
Sequoia
Interactive Broker
Refinitiv
Already have an account? Sign In Now
Full Insight
(Paid Plans Only)
Discussions
(Paid Plans Only)
WHAT’S TRENDING
Insights
  • Trending
  • Latest
Logo
Top Quartile
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
ChinaHealth CareEquity Bottom-UpThematic (Sector/Industry)
Price Chart(Sign Up to Access)
analytics-chart
  • Lepu Medical Technology A (300003 CH) - Does Not Have High Moat
    24 Feb 2021
  • Jinxin Fertility (1951.HK) - The New Policy, the Logic and the Risk Factors
    23 Feb 2021
  • China Healthcare Weekly (Feb.19) - VBP on Biosimilar Drugs, Poor Performance of Healthcare Sector
    22 Feb 2021
  • Innovent Biologics (1801 HK) - Have the Genes to Become a Big Pharma
    18 Feb 2021
  • Pre-IPO Betta Pharmaceuticals - Insights on Products and Concerns
    17 Feb 2021
  • Pre-IPO Joinn Laboratories - The Future Performance Is Worth Looking Forward To
    16 Feb 2021
  • InnoCare Pharma Ltd (9969.HK) - What Attracts Both Hillhouse and Vivo Capital?
    10 Feb 2021
  • Pre-IPO BeiGene - Would the IPO on the STAR Market Be the Last Hurrah?
    03 Feb 2021
x